Anti‐epidermal or anti‐vascular endothelial growth factor as first‐line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients

Publisher： John Wiley & Sons Inc

E-ISSN： 2190-6009|6|3|231-236

ISSN： 2190-5991

Source： Journal Of Cachexia Sarcopenia And Muscle, Vol.6, Iss.3, 2015-09, pp. : 231-236

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Retrospective Study as First-Line Chemotherapy Combined Anti-VEGF Antibody with Fluoropyrimidine for Frail Patients with Unresectable or Metastatic Colorectal Cancer

By  

Digestion, Vol. 87, Iss. 1, 2013-01 ,pp. : 59-64

Karger

Access to resources Recommend Favorite

Biomarkers for Predicting the Efficacy of Anti-Epidermal Growth Factor Receptor Antibody in the Treatment of Colorectal Cancer

By  

Digestion, Vol. 89, Iss. 1, 2014-01 ,pp. : 18-23

Karger

Access to resources Recommend Favorite

Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: A New Cause of Hypertension

By  

Current Hypertension Reviews, Vol. 3, Iss. 2, 2007-05 ,pp. : 149-155

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Vascular Endothelial Growth Factor Drug Treatment of Diabetic Macular Edema: The Evolution Continues

By  

Current Diabetes Reviews, Vol. 8, Iss. 4, 2012-07 ,pp. : 237-246

Bentham Science Publishers

Access to resources Recommend Favorite

FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping

By  

Medical Principles and Practice, Vol. 23, Iss. 5, 2014-03 ,pp. : 478-481

Karger

Access to resources Recommend Favorite